AST-021p Study in Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

November 30, 2023

Conditions
Advanced Cancer
Interventions
DRUG

AST-021p

3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization

Trial Locations (3)

Unknown

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Seoul ST. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aston Sci. Inc.

INDUSTRY

NCT04864418 - AST-021p Study in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter